These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1221 related articles for article (PubMed ID: 22928973)

  • 1. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
    Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
    Loeb S; Zhu X; Schroder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men.
    van den Bergh RC; Roemeling S; Roobol MJ; Aus G; Hugosson J; Rannikko AS; Tammela TL; Bangma CH; Schröder FH
    BJU Int; 2009 Jun; 103(11):1472-7. PubMed ID: 19154509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly.
    van den Bergh RC; Roemeling S; Roobol MJ; Aus G; Hugosson J; Rannikko AS; Tammela TL; Bangma CH; Schröder FH
    Eur Urol; 2009 Jan; 55(1):1-8. PubMed ID: 18805628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort.
    Seiler D; Randazzo M; Klotz L; Grobholz R; Baumgartner M; Isbarn H; Recker F; Kwiatkowski M
    BJU Int; 2012 Jul; 110(2):195-200. PubMed ID: 22093744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study.
    Bul M; Zhu X; Valdagni R; Pickles T; Kakehi Y; Rannikko A; Bjartell A; van der Schoot DK; Cornel EB; Conti GN; Boevé ER; Staerman F; Vis-Maters JJ; Vergunst H; Jaspars JJ; Strölin P; van Muilekom E; Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2013 Apr; 63(4):597-603. PubMed ID: 23159452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
    van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
    BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
    Roemeling S; Roobol MJ; Postma R; Gosselaar C; van der Kwast TH; Bangma CH; Schröder FH
    Eur Urol; 2006 Sep; 50(3):475-82. PubMed ID: 16713065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study.
    Bul M; Zhu X; Rannikko A; Staerman F; Valdagni R; Pickles T; Bangma CH; Roobol MJ
    Eur Urol; 2012 Aug; 62(2):195-200. PubMed ID: 22342775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early outcomes of active surveillance for localized prostate cancer.
    Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
    BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
    Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
    BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study.
    van den Bergh RC; Vasarainen H; van der Poel HG; Vis-Maters JJ; Rietbergen JB; Pickles T; Cornel EB; Valdagni R; Jaspars JJ; van der Hoeven J; Staerman F; Oomens EH; Rannikko A; Roemeling S; Steyerberg EW; Roobol MJ; Schröder FH; Bangma CH
    BJU Int; 2010 Apr; 105(7):956-62. PubMed ID: 19817747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes.
    Pfeiffer D; Berger J; Gross AJ
    BJU Int; 2012 Dec; 110(11):1702-7. PubMed ID: 22928703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active surveillance for the management of prostate cancer in a contemporary cohort.
    Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
    Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
    Loeb S; Berglund A; Stattin P
    J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam.
    Roobol MJ; Zhu X; Schröder FH; van Leenders GJ; van Schaik RH; Bangma CH; Steyerberg EW
    Eur Urol; 2013 Apr; 63(4):627-33. PubMed ID: 22841675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS).
    El Hajj A; Ploussard G; de la Taille A; Allory Y; Vordos D; Hoznek A; Abbou CC; Salomon L
    BJU Int; 2013 Jan; 111(1):53-9. PubMed ID: 22726582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program.
    Bul M; van den Bergh RC; Rannikko A; Valdagni R; Pickles T; Bangma CH; Roobol MJ
    Eur Urol; 2012 Feb; 61(2):370-7. PubMed ID: 21704447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.